CRVO Stock Analysis: Buy, Sell, or Hold?
CRVO - CervoMed Inc. Common Stock
$2.80
0.20 (7.69%)
▲
5d:
+9.37%
30d:
-21.57%
90d:
-24.32%
BUY
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 14, 2026
9d
Get Alerted When CRVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRVO is currently trading at $2.80, which is considered slightly low relative to its 30-day fair value range of $2.66 to $3.44.
Technical Outlook: Technically, CRVO is in a strong downtrend. Immediate support is located at $2.43, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: CRVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.20 (+585.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRVO is in a strong downtrend. Immediate support is located at $2.43, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: CRVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.20 (+585.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.66 -
$3.44
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.7%)
- BULLISH: Trading 585.7% below Wall St target ($19.20)
Trading Range Analysis
30-Day Trading Range
$2.66 -
$3.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.94
Current Trend
Strong Downtrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.12
Wall Street Target
$19.20
(+585.7%)
Revenue Growth (YoY)
-99.6%
Share & Embed Analysis
Last updated: August 04, 2026 5:12 PM ET
Data refreshes hourly during market hours. Next update: 6:12 PM
Data refreshes hourly during market hours. Next update: 6:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 42 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 48 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$57 | 55 HOLD |
